| Identification | Back Directory | [Name]
Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-, methyl ester | [CAS]
153559-48-9 | [Synonyms]
bexarotene methyl ester
Bexarotene Impurity Z4f
Methyl 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)
Methyl 4-(1-(3,5,5,8,8-pentaMethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate
methyl 4-<1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl>benzoate
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid methyl ester
Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-, methyl ester | [Molecular Formula]
C25H30O2 | [MDL Number]
MFCD16620614 | [MOL File]
153559-48-9.mol | [Molecular Weight]
362.5 |
| Chemical Properties | Back Directory | [Melting point ]
160-161 °C(Solv: ethyl acetate (141-78-6); methanol (67-56-1)) | [Boiling point ]
472.3±44.0 °C(Predicted) | [density ]
1.007±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Chloroform, Methanol (Slightly) | [form ]
Solid | [color ]
White to Light Beige |
| Hazard Information | Back Directory | [Uses]
Methyl Bexarotenate is a related compound of Bexarotene (B336750), which is an antineoplastic agent and a selective retinoid X receptor (RXR) agonist. | [Synthesis]
Methyl 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-carbonyl)benzoate was synthesized by Wittig reaction using methyltriphenylphosphonium bromide and methyl 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate as starting materials. During the synthesis, crystals of compound 35 were found to be suitable for X-ray diffraction analysis. To complete the synthesis of bexarotene, compound 35 was first subjected to Friedel-Crafts acylation using crude monomethyl terephthaloyl chloride (36) to give ketone 37. Subsequently, ketone 37 was converted to olefinic ester 38 by Wittig reaction. finally, olefinic ester 38 was subjected to saponification in the presence of potassium hydroxide followed by acidification with aqueous hydrochloric acid. to obtain the target product bexarotene (39) (Scheme 2). | [References]
[1] Journal of Medicinal Chemistry, 2009, vol. 52, # 19, p. 5950 - 5966
[2] Patent: WO2011/103321, 2011, A1. Location in patent: Page/Page column 19
[3] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[4] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
[5] Journal of Medicinal Chemistry, 1995, vol. 38, # 17, p. 3368 - 3383 |
|
| Company Name: |
SIMAGCHEM CORP
|
| Telephone: |
+86-5922680277 +86-13806087780 |
| Website: |
http://www.simagchem.com/ |
| Company Name: |
Energy Chemical
|
| Telephone: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Wuhan Topule
|
| Telephone: |
+86-02787215551 19945035818 |
| Website: |
http://www.topule.com/ |
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|